B-cell prolymphocytic leukemia (B-PLL) is a very rare and typically aggressive cancer characterized by the out-of-control growth of B cells (or B lymphocytes), which are a type of white blood cell that is part of the immune system.
B-PLL usually affects older adults with a median age of 69 at diagnosis and is slightly more common in men than women. Most of the time, B-PLL occurs as a transformation or evolution of a more slow-growing B-cell cancer, such as chronic lymphocytic leukemia (CLL). Rarely, is this a primary disorder.
Signs and symptoms of B-PLL
Common signs and symptoms of B-PLL include the following:
- High lymphocyte count
- Enlarged spleen (called “splenomegaly”)
- B symptoms
- Fevers
- Night sweats
- Weight loss
- Low red blood count (called “anemia")
- Low platelet count (called “thrombocytopenia")
Diagnosing B-PLL
B-PLL is extremely rare and accurately diagnosing it can be difficult, as B-PLL has similar clinical presentation to other mature B-cell malignancies, including CLL, mantle cell lymphoma, and splenic marginal zone lymphoma. Therefore, it is important that an experienced hematopathologist examines and interprets a patient's lab results.
A hematopathologist is a doctor who specializes in examining tissue and diagnosing disease. B-PLL is diagnosed when more than 55 percent of the lymphocytes in the peripheral blood are prolymphocytes (immature lymphocytes), or when a lymph node or bone marrow sample shows that the majority of lymphocytes are prolymphocytes.
The genetic features causing B-PLL are largely unknown. Abnormalities of the TP53 gene (deletion and/or mutation) are seen in about 50 percent of cases and abnormalities of MYC gene are seen in about 50 percent of cases. Some patients have abnormalities in both genes.
Tests used to diagnose B-PLL include the following:
- Complete blood count (CBC)
- Peripheral blood smear
- Bone marrow biopsy/aspiration
- Immunophenotyping by flow cytometry
- Cytogenetics by either karyotyping or FISH
- Molecular testing
Learn more about the lab and imaging tests doctors use to diagnose B-PLL.
Types of treatment for B-PLL
There is no consensus on treatment strategy. Currently, B-PLL is not considered curable with standard treatments, except for a possible hematopoietic stem cell transplantation, available only to a few younger and/or fitter patients. Therefore, patients are encouraged to enroll in clinical trials whenever possible.
Clinical trials can involve new drugs, new combinations of drugs, or previously approved drugs being studied in new ways, such as new drug doses or new schedules to administer the drugs. Clinical trials are conducted worldwide under rigorous guidelines to help doctors find out whether new cancer treatments are safe and effective, or better than the standard treatment.
Learn more about clinical trials.
Get free clinical trial support! Visit our Clinical Trial Support Center (CTSC).
Connect with registered nurses with expertise in blood cancers who can personally assist you or your caregiver through each step of the clinical trial process.
Current treatment approaches for B-PLL include the following:
Watch and wait: For the approximately 10 percent to 15 percent of B-PLL patients who do not have symptoms at the time of diagnosis, their recommended treatment may be the “watch-and-wait” approach, meaning treatment is deferred or delayed until signs and symptoms of the disease appear or progress. Since B-PLL can progress rapidly, frequent monitoring, including blood tests, is necessary so that treatment can be started if the disease starts advancing.
Learn more about watch and wait.
Drug therapy: B-PLL is most commonly treated with chemo-immunotherapy combinations used to treat CLL. Common regimens include FCR (fludarabine [Fludara®], cyclophosphamide [Cytoxan®], rituximab [Rituxan®]) or BR (Bendamustine [Treanda®], Rituximab [Rituxan®]).
Patients with mutations of the TP53 gene are typically resistant to conventional therapies and may be treated with the monoclonal antibody alemtuzumab (Campath®). Researchers are studying new therapies that target B-cell signaling, such as ibrutinib (Imbruvica®) and idelalisib (Zydelig®) for patients who are unable to tolerate intensive therapies and/or who have TP53 abnormalities. While ibrutinib and idelalisib have not currently been approved by the FDA to treat B-PLL, they have been approved to treat other B-cell malignancies.
Learn more about drug therapy. For information about the drugs listed on this page, visit our cancer drug listing.
Hematopoietic stem cell transplantation: In patients who achieve a remission following initial drug therapy, a stem cell transplantation is a treatment option that may offer a potential cure. Stem cell transplantation may be considered in younger, fitter patients who have responded to their initial therapy. Unfortunately, most patients with B-PLL are not fit enough for such an intensive treatment. This said, in recent years, the introduction of reduced-intensity regimens has made this treatment option available to more patients.
Learn more about stem cell transplantation.
Reviewed by: Jennifer Woyach, MD
References
Dearden C. How I treat prolymphocytic leukemia. Blood 2012;120(3):538-551.
Dearden C. Management of prolymphocytic leukemia. Hematology AM Soc Hematol Educ Program. 2015;2015:361-367.
Freedman AS, Aster JC, Dearden C. B-cell prolymphocytic leukemia. In UpToDate.
Get free, one-on-one support
Call, email, or chat with a member of our highly trained support team.
Blood Cancer United resources
Find free, specialized guidance and information for every type of blood cancer, request financial support, find emotional support, and connect with other members of the blood cancer community.
